Shelf-Life Extension for Specific Lots of Paxlovid
January 18, 2023
Therapeutics Update
View the COVID-19 Therapeutic Product Expiration Dates Database for the most recent shelf-life extension and product expiration information.
The COVID-19 pandemic is rapidly evolving, and new updates are issued frequently. To view a full list of HHS/ASPR’s updates related to COVID-19 monoclonal antibody therapeutics, please see our
full list of updates.
The Administration for Strategic Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) announces the authorization of a shelf life extension to 24 months for the Pfizer antiviral therapy, Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use), which is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients (12 years of age and older weighing at least 40kg).
As a result of this extension, be sure to check all inventory for the extended expiration dates. As required by the emergency use authorization, unopened cartons of Paxlovid (300 mg nirmatrelvir and 100 mg ritonavir, or 150 mg nirmatrelvir and 100 mg ritonavir), must be appropriately held in accordance with storage conditions detailed in the authorized
Fact Sheet for Health Care Providers. FDA granted this extension following a thorough review of data submitted by Pfizer. To find out the expiry date extension on your product, please download the data tables.
PAXLOVID consists of 2 medicines: nirmatrelvir tablets and ritonavir tablets. The 24-month expiry date is based on the earliest date of manufacture between the two components. Due to this nuance, some product that initially had the same expiry will now have different expiry dates.
Download Data by Date (391KB PDF)
Download Data by Batch Number (291KB PDF)
Download All Data (29KB XLS)
